Sen. Wyden urges FDA to issue ‘discretion policy,’ interim rule on CBD in...
A U.S. senator characterized as “fully unacceptable” a suggestion by FDA that publishing a final rule authorizing the use of hemp-derived CBD in dietary supplements could take three to five years.
View ArticleFDA officials ponder definitions of ‘hemp extracts,’ ‘THC-free’ at CBD hearing
A public hearing hosted by FDA highlighted the complexities of key terms whose meanings have neither been clearly defined by the hemp industry nor the federal government.
View ArticleIowa AG warns of potential criminal actions against CBD marketers
Iowa officials warned CBD products won’t necessarily be legal even after they are removed from the list of controlled substances under state law.
View ArticleAmarin plans another fight against concentrated EPA supplements
Amarin, the manufacturer of the pharmaceutical drug Vascepa, has devised a new strategy in its long-running grievances against the dietary supplement sector.
View ArticleFDA must ‘step up enforcement' against CBD products
The Consumer Healthcare Products Association (CHPA) is among several groups urging FDA to increase its enforcement against products containing CBD, a hemp-derived compound that has proliferated in...
View ArticleAGs urge FDA to preserve states’ CBD regulatory role
In a letter to FDA's top official, a group of 37 state attorneys general suggested companies supplying CBD products, FDA and the states should all share in responsibility for protecting consumers.
View ArticleTrade groups weigh path forward for CBD in dietary supplements
The Council for Responsible Nutrition and Natural Products Association have expressed differing views on how FDA should proceed as it eyes a regulatory framework for CBD in dietary supplements.
View ArticleHemp association to lawmakers: Limit Farm Bill felony ban
The 2018 Farm Bill legalized hemp, but it also imposed certain restrictions on individuals convicted within the past 10 years of a felony for a controlled substance.
View ArticleGW to FDA: CBD consumer goods hurt cannabis drug development
Comments filed by GW Pharmaceuticals underscored a chief challenge facing FDA as it looks at potentially authorizing CBD in conventional food and dietary supplements: preserving incentives for the...
View ArticleAmarin asks Supreme Court to hear dispute involving omega-3 supplements
Amarin is making a final effort in the federal judiciary to compel the U.S. International Trade Commission to investigate its complaint over the legality of certain “synthetically produced omega-3...
View ArticleCBD sales violate ethics code
In a memo first reported by Direct Selling News, ethics code administrator Jared Blum concluded, “The present sale of ingestible CBD products is illegal under federal law and hence violates the DSA...
View ArticleChina health products probe dampens results for multi-level marketers
A 100-day government review of health products in China has weighed down multi-level marketers' second-quarter sales and hurt forecasts—at least temporarily.
View ArticleMegaFood among those requesting EPA reduce glyphosate residues in oats
MegaFood in May hosted a rally in the nation's capital over a 2018 petition to EPA to reduce the tolerance level of glyphosate in oats and explicitly prohibit its use as a pre-harvest desiccant.
View ArticleFDA wins appeal over DMAA in dietary supplements
A decision Friday by the U.S. Court of Appeals for the Eleventh Circuit marked a victory for FDA and a loss for a dietary supplement manufacturer—Hi-Tech Pharmaceuticals—over the legality of an...
View ArticleU.S. exceeds half million licensed hemp acres
Nearly 17,000 farmers and researchers received state licenses this year to cultivate hemp, a 476% increase over 2018, Vote Hemp reported.
View ArticleCourt decision lends support to synthetic botanicals in supplements
The U.S. Court of Appeals for the Eleventh Circuit offered an analysis on synthetical botanicals and dealt what could be the final blow to DMAA (1,3-dimethylamylamine), a once-popular and controversial...
View ArticleCourt rejects claim FDA needed rulemaking in DMAA case
Was FDA required to engage in a rulemaking before targeting DMAA products in an enforcement action? Not according to a federal appeals court.
View ArticleFTC warns more CBD marketers over disease claims
The FTC warned three marketers of CBD in letters that it is illegal to advertise a product can cure, prevent or treat a human disease without competent and reliable scientific evidence to support the...
View ArticleFTC eyes more aggressive action against CBD disease claims
An FTC official signaled his agency will take more aggressive enforcement action against marketers of CBD in the future, moving beyond warning letters and instead issuing civil investigative demands.
View ArticleTrucker carrying hemp through Idaho reaches plea agreement
A truck driver hauling hemp through Idaho has reached a plea agreement that will keep him out of jail, but the Colorado-based company whose hemp was seized is still awaiting a resolution to a dispute...
View Article
